CHST3

Across TCGA pan-cancer cohorts, CHST3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CHST3 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CHST3 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHST3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUAD show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where CHST3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.182	0.450	.002	49	view →
LSCC	OS	Quartile	II,III,IV	0.538	0.927	.009	7	view →
UCEC	DFS	Quartile	All	1.000	0.719	.010	4	view →
CCRCC	OS	Median	III,IV	0.414	0.985	.038	2	view →
LUAD	DFS	Median	III,IV	1.000	0.886	.021	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CHST3–PDAC (DFS)

Open the PDAC breakdown →